A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
(ASCEND Trial)
Recruiting in Palo Alto (17 mi)
+44 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Satsuma Pharmaceuticals, Inc.
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Research Team
DA
Detlef Albrecht, MD
Principal Investigator
Satsuma Pharmaceuticals, Inc.
Eligibility Criteria
Inclusion Criteria
International Classification of Headache Disorder, 3rd Edition (ICHD3)
You are male or female, 18-65 years of age at the time of Screening Visit.
Subject has at least 1-year history of migraines (with or without aura), according to the
Treatment Details
Interventions
- Dihydroergotamine (Ergot Alkaloid)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: STS101Experimental Treatment1 Intervention
STS101 (dihydroergotamine nasal powder)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Satsuma Pharmaceuticals, Inc.
Lead Sponsor
Trials
5
Recruited
3,400+